Your browser doesn't support javascript.
loading
Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population.
Lee, Shou Wu; Tung, Chun Fang; Peng, Yen Chun; Lien, Han Chung; Chang, Chi Sen.
Afiliación
  • Lee SW; Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan Province, China.
  • Tung CF; Department of Internal Medicine, Chung Shan Medical University, Taichung, Taiwan Province, China.
  • Peng YC; Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan Province, China.
  • Lien HC; Department of Internal Medicine, YangMing University, Taipei, Taiwan Province, China.
  • Chang CS; Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan Province, China.
J Dig Dis ; 21(8): 462-467, 2020 Aug.
Article en En | MEDLINE | ID: mdl-32472590

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimioembolización Terapéutica / Carcinoma Hepatocelular / Sorafenib / Neoplasias Hepáticas / Antineoplásicos Tipo de estudio: Evaluation_studies / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Dig Dis Año: 2020 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimioembolización Terapéutica / Carcinoma Hepatocelular / Sorafenib / Neoplasias Hepáticas / Antineoplásicos Tipo de estudio: Evaluation_studies / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Dig Dis Año: 2020 Tipo del documento: Article País de afiliación: China
...